SCHEMBL30795015

SCHEMBL30795015

Cc1cc(N2CCOCC2)nc(N(C)C)c1C(=O)NCc1ccc(F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPEPLD Q6IQ20 1/20 0.48
TP53 P04637 2/20 0.48
ALDH1A1 P00352 2/20 0.47
GAA P10253 2/20 0.47
TSHR P16473 1/20 0.47
KCNQ3 O43525 1/20 0.46
KCNQ2 O43526 1/20 0.46
LMNA P02545 4/20 0.45
PIK3CA P42336 2/20 0.45
PIK3CG P48736 2/20 0.45
KMT2A Q03164 1/20 0.44
THRB P10828 1/20 0.44
PIK3CB P42338 1/20 0.43
KLKB1 P03952 1/20 0.43
KLK1 P06870 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GLA P06280 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2130845 1.00 NAPEPLD (0.48) NAPEPLDTP53ALDH1A1GAATSHR
SCHEMBL30795920 0.92 NAPEPLD (0.48) NAPEPLDTP53ALDH1A1GAATSHR
SCHEMBL2130075 0.92 NAPEPLD (0.48) NAPEPLDTP53ALDH1A1GAATSHR
SCHEMBL2131385 0.91 NAPEPLD (0.47) NAPEPLDLMNAPIK3CAPIK3CGPIK3CB
SCHEMBL2129241 0.91 PPARG (0.48) NAPEPLDTP53ALDH1A1KCNQ3KCNQ2
SCHEMBL2132334 0.90 MEN1 (0.52) NAPEPLDTP53ALDH1A1TSHRLMNA
SCHEMBL2129755 0.90 NAPEPLD (0.48) NAPEPLDALDH1A1LMNAPIK3CAPIK3CG
SCHEMBL2129332 0.90 NAPEPLD (0.50) NAPEPLDGAALMNA
SCHEMBL30795808 0.90 NAPEPLD (0.48) NAPEPLDALDH1A1LMNAPIK3CAPIK3CG
SCHEMBL30794770 0.90 NAPEPLD (0.50) NAPEPLDGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed